SERPINE1 and melanoma: To prove this hypothesis, from September 2021, we have started a phase II study investigating the safety and efficacy of TM5614, a novel PAI-1 inhibitor with better oral bioavailability that selectively inhibits PAI-1 activity (18), in combination with nivolumab in the treatment of unresectable malignant melanoma (jRCT2021210029).